Atlas Bio wants to retire Phase II trials and animal testing
Seven in ten drugs die during Phase II, and each death burns…
Bristol Myers puts $3B-plus tag on Pathos AI platform for cancer models
Pathos AI has banked $237M in Series E money led by Bristol…
AstraZeneca bets up to $1.5B that machine learning can find liver drugs
The pharma major is tying a biobucks-heavy collaboration to insitro's models for…
Isomorphic Labs seeks a $40B price tag ahead of its first trial
Isomorphic Labs is reportedly in early talks to raise at a valuation…
Isomorphic Labs chases a $50B valuation for AI drug discovery
Isomorphic Labs is reportedly raising at a $40B to $50B valuation for…
Enveda collects $311M to push plant chemistry drugs forward
Catalio Capital Management led the Series E for a platform that reads…
London’s Basecamp Research collects $140M to design DNA medicines
Anthropic's Anthology Fund and Nvidia join a round that will fund biological…
HSG leads $290M for ByteDance’s spun-out AI drug lab
Anew Labs, the AI drug discovery business ByteDance spun off, has closed…
